$22 out-of-pocket costs
for many eligible patients;
restrictions apply

The NAFTIN GEL 2% co‑pay savings program⁸

Help patients save on prescriptions

$22 out-of-pocket costs for many eligible patients; restrictions apply
Offer not valid for patients covered by Medicare, Medicaid, or any federal or state pharmaceutical assistance programs

Print Savings Card

ELIGIBILITY CRITERIA & TERMS:

This savings card is not valid for use by patients covered by any federal or state funded healthcare program (including, but not limited to, Medicare (Part D and Medigap), Medicaid, any state pharmaceutical assistance program, TRICARE, VA, or DoD), or private indemnity or HMO insurance plans that reimburse patient for the entire cost of prescription drugs. Offer good only in the U.S., including Puerto Rico. Not valid if an AB-rated generic drug is available for the product. Void where prohibited by law, taxed, or restricted. This offer cannot be combined with any other promotional offer. Legacy Pharma Inc. SEZC reserves the right to rescind, revoke, or amend this offer without notice at any time. No cash value. Not eligible for sale, purchase, trade or counterfeit.

ExpandCollapseClick to expand complete Important Safety Information.Close

INDICATIONS AND USAGE: NAFTIN GEL 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS: In clinical trials with NAFTIN GEL 2%, the most common adverse reactions (2%) were application site reactions.

WARNINGS AND PRECAUTIONS: If redness or irritation develops with the use of NAFTIN GEL 2%, treatment should be discontinued.

Please click here for full Prescribing Information about NAFTIN GEL 2%.

REFERENCES: 1. Vlahovic TC. Choosing the right vehicle. Podiatr Manage. June/July 2008;209-214. 2. Data on file, Legacy Pharma Inc. SEZC. 3. Naftin Gel 2%. Package insert. Legacy Pharma Inc. SEZC; 2020. 4. Graybill JR, Burgess DS, Hardin TC. Key issues concerning fungistatic versus fungicidal drugs. Eur J Clin Microbiol Infect Dis. 1997;16(1):42-50. 5. Plaum S, Verma A, Fleischer AB, Olayinka B, Hardas B. Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream or gel 2%. J Drugs Dermatol. 2013;12(9):1004-1008. 6. Stein Gold L, Parish L, Vlahovic T, Kircik L, et al. Efficacy and safety of naftifine HCL Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials. J Drugs Dermatol. 2013;12(8):911-918. 7. Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol. 1997;36:S3-S8. 8. NAFTIN 2% Co-Pay Savings Offer. Legacy Pharma Inc. SEZC, 2023. 9. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. November 2011;10(11):1282-1288. 10. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. October 2011;10(10):1142-1147. 11. Robbins CM, Elston DM. Tinea pedis treatment & management. Updated September 11, 2020. Accessed December 14, 2022. https://emedicine.medscape.com/article/1091684-treatment#showall 12. Phillips, RM, Rosen T. Topical antifungal agents. Allylamines and benzylamines. In: Wolverton, SE, ed. Comprehensive Dermatologic Drug Therapy. 3rd ed. Elsevier Inc. Ebook; 2013:460-472. 13. IQVIA. National Prescription Audit Report. October 2022.